Saturday - January 24, 2026
Trelegy Ellipta Approved in China for Use in Adults With Uncontrolled Asthma
January 24, 2026
LONDON, England, Jan. 24 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Jan. 23, 2026:

* * *

Trelegy Ellipta approved in China for use in adults with uncontrolled asthma

- Asthma indication introduces an important option for patients with uncontrolled symptoms

- Approval adds to existing indication in COPD, making Trelegy Ellipta the only single inhaler triple therapy available for both resp . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products